Valiant Laboratories Limited

BSE: VALIANTLAB543998ISIN INE0JWS01017

Healthcare
Pharmaceuticals

Share price

₹121.05-2.45 (-1.98%)

as of 4 Nov 2026

Prices adjusted for splits and bonuses; cash dividends excluded. Volume shows actual shares traded. Earlier history is omitted pending corporate-action verification.

52W high: ₹141.30
52W low: ₹50.00
Off 52W high: -14.33%
1M return: -3.55%
3M return: +96.03%
6M return: +52.15%
1Y return: +45.84%
20D avg volume: 6,843
50 DMA: ₹119.74
200 DMA: ₹79.77

Key ratios Consolidated

Market cap: ₹657.45 Cr
Current price: ₹121.05
52W high / low: ₹141.30 / ₹50.00
Face value: ₹10.00
P/E: 40.54
P/B: 1.98
EPS (TTM): ₹2.99
Book value / share: ₹61.20
ROE: —
ROCE: 0.80%
Operating margin: —
Net margin: —
Debt / equity: 0.14
Net debt: ₹41.42 Cr
Interest cover: 1.41
Dividend yield: —
Dividend / share (TTM): —
Payout: —
Cash conversion cycle: 69.1 days

Financials

Metric	Q2 FY27	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24
Income statement
	116.77	115.29	91.98	52.46	46.20	46.82	57.79	35.23	21.48	18.88	30.59	40.52
	0.11	0.86	0.17	0.63	0.87	0.66	-2.31	1.58	3.36	2.81	2.50	1.77
	116.89	116.15	92.15	53.09	47.07	47.48	55.47	36.81	24.84	21.70	33.09	42.29
	116.22	89.95	91.11	56.08	46.79	45.03	54.53	35.19	28.75	21.86	35.66	47.34
	89.65	62.35	68.46	44.50	42.37	35.46	46.78	29.28	16.68	19.68	30.69	37.84
	0.03	11.61	2.48	1.86	0.00	4.70	0.28	—	—	—	—	—
	2.93	2.60	2.56	1.95	1.29	1.20	1.13	1.11	1.19	0.96	1.26	1.21
	0.96	1.07	1.01	0.68	0.14	0.07	0.06	0.06	0.01	0.05	0.02	0.02
	3.66	2.86	2.93	2.05	0.53	0.53	0.52	0.52	0.52	0.54	0.52	0.49
	11.76	15.67	12.47	6.43	4.51	3.51	4.61	4.78	6.44	1.31	3.85	4.49
	0.67	26.19	1.05	-2.99	0.28	2.45	0.94	1.62	-3.91	-0.16	-2.57	-5.04
	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	0.67	26.19	1.05	-2.99	0.28	2.45	0.94	1.62	-3.91	-0.16	-2.57	-5.04
	0.26	5.09	-0.71	4.07	0.08	0.63	0.24	0.73	0.83	0.35	1.33	1.54
	0.41	21.10	1.76	-7.06	0.20	1.82	0.70	2.35	-4.74	-0.51	-1.24	-3.50
	0.08	3.89	0.32	-1.30	0.04	0.42	0.16	0.54	-1.09	-0.12	-0.33	-0.81
Key metrics
	5.29	30.12	4.99	-0.26	0.95	3.05	1.52	2.20	-3.38	0.43	-2.03	-4.53
	4.50%	26.10%	5.40%	-0.50%	2.10%	6.50%	2.60%	6.20%	-15.70%	2.30%	-6.60%	-11.20%
	0.40%	18.30%	1.90%	-13.50%	0.40%	3.90%	1.20%	6.70%	-22.10%	-2.70%	-4.10%	-8.60%
	0.50%	—	0.60%	—	0.10%	—	0.30%	—	—	—	—	—
	152.70%	146.20%	59.20%	48.90%	115.10%	148.00%	88.90%	-13.10%	—	—	—	—
	105.00%	1,059.30%	151.40%	-400.40%	104.20%	456.90%	156.50%	167.10%	—	—	—	—

Metric	TTM	FY26	FY25	FY24
Income statement
	376.50	237.47	133.38	182.06
	1.77	2.32	5.43	9.68
	378.28	239.79	138.82	191.74
	353.36	239.02	140.33	192.51
	264.96	190.80	112.18	169.39
	15.98	9.04	0.56	0.45
	10.04	7.00	4.39	4.31
	3.72	1.90	0.18	0.08
	11.50	6.04	2.09	1.97
	46.33	26.92	17.07	17.90
	24.92	0.77	-1.51	-0.77
	0.00	0.00	0.00	0.00
	24.92	0.77	-1.51	-0.77
	8.71	4.04	0.69	1.09
	16.21	-3.27	-2.20	0.32
	2.99	-0.51	-0.51	0.13
Key metrics
	40.14	8.71	0.76	1.28
	10.66%	3.70%	0.60%	0.70%
	4.31%	-1.40%	-1.60%	0.20%
	—	0.80%	-0.40%	—
	102.38%	78.00%	-26.70%	—
	219.72%	-48.60%	-787.50%	—
	—	-44.63	-112.54	—
	—	3.19	-0.60	—
	—	0.14	0.52	—
	—	41.42	116.29	—
	—	69.1	96.9	—
Balance sheet
	—	463.98	400.86	—
	—	228.32	192.62	—
	—	3.53	4.92	—
	—	93.56	72.12	—
	—	45.43	3.99	—
	—	54.46	38.26	—
	—	227.01	48.33	—
	—	94.02	40.72	—
	—	119.45	59.62	—
	—	44.95	121.21	—
	—	16.86	16.86	—
	—	28.09	104.35	—
	—	310.89	234.31	—
Cash flow
	—	-10.43	1.31	—
	—	7.25	-52.77	—
	—	1.79	44.65	—
	—	34.20	113.85	—

Metric	Q2 FY27	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24
Income statement
	72.43	73.42	65.30	54.74	45.99	51.01	57.77	35.23	21.48	18.88	30.58	40.52
	0.41	0.85	0.77	0.61	0.85	0.67	0.65	0.67	1.93	2.17	2.50	1.77
	72.85	74.27	66.08	55.35	46.83	51.68	58.42	35.90	23.41	21.06	33.09	42.29
	70.95	61.55	61.34	55.24	46.58	49.23	54.50	35.18	28.73	21.83	35.64	47.34
	63.99	46.21	49.50	40.15	42.18	39.69	46.77	29.26	16.68	19.68	30.68	37.85
	0.03	11.61	2.48	8.39	0.00	4.70	0.28	—	—	—	—	—
	1.52	1.22	1.29	1.24	1.28	1.19	1.13	1.11	1.19	0.96	1.26	1.21
	0.09	0.08	0.02	0.03	0.14	0.07	0.05	0.06	0.01	0.05	0.02	0.02
	0.57	0.55	0.52	0.72	0.51	0.51	0.51	0.51	0.51	0.50	0.50	0.49
	2.92	4.17	5.34	4.21	4.50	3.50	4.60	4.78	6.44	1.31	3.85	4.48
	1.89	12.73	4.74	0.11	0.26	2.45	3.92	0.72	-5.32	-0.77	-2.55	-5.04
	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—	—	—
	1.89	12.73	4.74	0.11	0.26	2.45	3.92	0.72	-5.32	-0.77	-2.55	-5.04
	0.44	3.25	1.20	0.08	0.09	0.63	0.69	0.88	0.66	0.23	1.33	1.54
	1.45	9.48	3.53	0.03	0.17	1.82	3.24	1.60	-5.98	-1.01	-1.22	-3.50
	0.27	1.75	0.65	0.01	0.03	0.42	0.74	0.37	-1.39	-0.23	-0.32	-0.81
Key metrics
	2.55	13.36	5.28	0.86	0.91	3.03	4.48	1.29	-4.80	-0.22	-2.03	-4.53
	3.50%	18.20%	8.10%	1.60%	2.00%	5.90%	7.80%	3.70%	-22.30%	-1.20%	-6.60%	-11.20%
	2.00%	12.90%	5.40%	0.10%	0.40%	3.60%	5.60%	4.50%	-27.80%	-5.30%	-4.00%	-8.60%
	0.60%	—	1.50%	—	0.10%	—	1.30%	—	—	—	—	—
	57.50%	43.90%	13.00%	55.40%	114.10%	170.20%	88.90%	-13.10%	—	—	—	—
	752.90%	420.90%	9.00%	-98.10%	102.80%	280.20%	365.60%	145.70%	—	—	—	—

Metric	TTM	FY26	FY25	FY24
Income statement
	265.89	217.04	133.36	182.05
	2.64	2.90	5.43	9.68
	268.55	219.94	138.79	191.73
	249.08	212.39	140.24	192.49
	199.85	171.53	112.16	169.39
	22.51	15.57	0.56	—
	5.27	5.00	4.39	4.31
	0.22	0.26	0.18	0.08
	2.36	2.26	2.02	1.95
	16.64	17.56	17.07	17.90
	19.47	7.55	-1.45	-0.75
	0.00	0.00	0.00	—
	19.47	7.55	-1.45	-0.75
	4.97	2.00	0.70	1.09
	14.49	5.55	-2.15	0.34
	2.68	1.02	-0.50	0.14
Key metrics
	22.05	10.07	0.75	1.28
	8.29%	4.60%	0.60%	0.70%
	5.45%	2.60%	-1.60%	0.20%
	—	2.40%	-0.40%	—
	39.94%	62.70%	-26.70%	—
	112.15%	358.10%	-732.40%	—
	—	-14.97	-22.46	—
	—	-2.49	10.19	—
	—	0.00	0.25	—
	—	-3.07	54.60	—
	—	77.4	155.0	—
Balance sheet
	—	385.89	317.28	—
	—	189.32	119.22	—
	—	3.07	4.80	—
	—	83.25	72.10	—
	—	22.97	3.96	—
	—	49.67	14.30	—
	—	29.59	29.94	—
	—	60.18	19.40	—
	—	62.68	20.95	—
	—	0.00	59.40	—
	—	0.00	0.00	—
	—	0.00	59.40	—
	—	319.76	234.38	—
Cash flow
	—	-13.81	-21.90	—
	—	-8.09	24.97	—
	—	20.17	-0.50	—
	—	1.16	0.56	—

Compounded growth

Standalone

Sales CAGR 3Y: —
Sales CAGR 5Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Sales YoY (TTM): +39.94%
Profit YoY (TTM): +112.15%

Consolidated

Sales CAGR 3Y: —
Sales CAGR 5Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Sales YoY (TTM): +102.38%
Profit YoY (TTM): +219.72%

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Sep 2026

Promoter holding: 74.95%

Quarter	September 2026	June 2026
Promoter %	74.95%	74.95%

Holder	Type	Holding	Previous	Change
Dhanvallabh Ventures LLP	Promoter	46.84%	46.84%	0.00%
Santosh Shantilal Vora	Promoter	7.50%	7.50%	0.00%
Shantilal Shivji Vora	Promoter	7.50%	—	—
Paresh Shashikant Shah	Promoter Group	7.49%	9.36%	-1.87%
Kanchan Shantilal Vora	Promoter Group	3.72%	3.72%	0.00%
Chandrakant Vallabhaji Gogri	Promoter Group	1.87%	—	—
Anil Vishanji Dedhia	Public	1.84%	1.84%	0.00%
Rachi Santosh Vora	Promoter Group	0.02%	0.02%	0.00%
Varsha Paresh Shah	Promoter Group	0.01%	0.01%	0.00%
Shantilal Vora and Sons LLP	Promoter Group	0.00%	—	—
Sagar Chemicals	Promoter Group	0.00%	—	—
Chanchal Himmatlal Chheda	Promoter Group	0.00%	—	—
Kalpana Rajesh Shah	Promoter Group	0.00%	—	—
Astha Manoj Jain	Promoter Group	0.00%	—	—
Chetan Dresses	Promoter Group	0.00%	—	—

Public shareholders are disclosed individually only above 1%.

Peer comparison

Company	Mkt cap (₹ Cr)	Price (₹)	P/E	ROCE	Sales YoY	Profit YoY	1Y return
Sun Pharmaceutical Industries Ltd.	4,26,112	1,776.00	38.78	17.90%	+12.13% TTM	+4.79% TTM	+4.92%
Divi's Laboratories Ltd.	2,66,424	10,036.00	91.09	19.00%	+16.35% TTM	+26.84% TTM	+47.61%
Torrent Pharmaceuticals Ltd.	1,79,908	4,730.00	85.71	9.10%	+42.06% TTM	-1.92% TTM	+32.24%
Laurus Labs Limited	1,24,601	2,306.10	93.53	19.70%	+23.03% TTM	+95.38% TTM	+134.59%
Zydus Lifesciences Limited	1,18,703	1,190.00	25.85	19.20%	+21.11% TTM	-2.51% TTM	+22.32%
Dr. Reddy's Laboratories Ltd.	1,14,513	1,372.00	41.50	13.90%	-3.53% TTM	-51.90% TTM	+14.26%
Cipla Ltd.	1,13,110	1,400.10	39.63	14.90%	-0.74% TTM	-47.48% TTM	-6.88%
Mankind Pharma Limited	1,04,631	2,533.15	46.22	13.70%	+13.27% TTM	+27.60% TTM	+6.91%
Aurobindo Pharma Ltd.	97,878	1,701.10	26.38	13.60%	+9.09% TTM	+9.48% TTM	+47.79%
Lupin Ltd	92,145	2,015.00	17.65	28.40%	+24.22% TTM	+20.10% TTM	+0.84%
Glenmark Pharmaceuticals ltd	70,608	2,501.85	39.27	16.20%	+32.94% TTM	+138.48% TTM	+35.48%
Alkem Laboratories Limited	62,054	5,190.00	28.15	18.80%	+13.36% TTM	-5.52% TTM	-8.38%
Abbott India Ltd. S	57,685	27,146.85	35.73	41.90%	+6.29% TTM	+11.18% TTM	-7.56%
Biocon Ltd.	56,061	344.00	134.63	2.90%	+5.70% TTM	-55.37% TTM	-9.53%
Gland Pharma Limited	52,105	3,157.70	46.16	13.70%	+17.57% TTM	+46.55% TTM	+65.09%
Ipca Laboratories Ltd.	50,051	1,973.15	36.40	16.40%	+10.59% TTM	+67.91% TTM	+52.33%
GlaxoSmithkline Pharmaceuticals Ltd.	42,904	2,532.60	37.42	55.40%	+12.12% TTM	+20.03% TTM	-4.84%
Ajanta Pharma Ltd.	41,406	3,313.55	32.79	29.40%	+25.01% TTM	+29.70% TTM	+26.89%
Emcure Pharmaceuticals Limited	41,254	2,174.55	37.75	25.10%	+21.12% TTM	+33.34% TTM	+64.07%
J.B. Chemicals & Pharmaceuticals Lt	38,731	2,412.25	47.77	21.90%	+5.87% TTM	+7.56% TTM	+45.79%
Sai Life Sciences Limited	32,855	1,546.30	90.80	18.10%	—	—	+67.49%
PIRAMAL PHARMA LIMITED	31,659	237.80	-151.21	0.80%	+9.43% TTM	-781.93% TTM	+18.60%
ACUTAAS CHEMICALS LIMITED	30,928	3,777.65	70.51	27.70%	+45.18% TTM	+95.78% TTM	+106.30%
Wockhardt Ltd	30,869	1,899.80	76.22	6.40%	+25.70% TTM	+894.12% TTM	+39.18%
RUBICON RESEARCH LIMITED	28,416	1,716.55	98.59	24.30%	—	—	+164.06%
Valiant Laboratories Limited	657	121.05	40.54	0.80%	+102.38% TTM	+219.72% TTM	+45.84%

Filings & corporate actions

Recent announcements

Copy of Newspaper Publication of Financial Results for quarter and half year ended September 30, 2026.4 Nov 2026 · Company Update / Newspaper Publication
Audited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2026.2 Nov 2026 · Result / Financial Results
Audited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2026.2 Nov 2026 · Board Meeting / Outcome of Board Meeting
Valiant Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/11/2026 ,inter alia, to consider and approve financial results for ....27 Oct 2026 · Board Meeting / Board Meeting
Please find enclosed13 Oct 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Closure of Trading Window for declaration of Financial Results for the quarter and half year ended September 30, 2026.29 Sep 2026 · Insider Trading / SAST / Closure of Trading Window
Scrutinizer''s Report and Voting Results of 5th AGM of Valiant Laboratories Limited.29 Sep 2026 · AGM/EGM / AGM
Scrutinizer''s Report and Voting Results of 5th AGM of Valiant Laboratories Limited.29 Sep 2026 · AGM/EGM / AGM
Proceedings of 5th Annual General Meeting of Valiant Laboratories Limited held through VC/OAVM.28 Sep 2026 · AGM/EGM / AGM
Please find enclosed17 Sep 2026 · Others / Outcome without intimation
Please find enclosed17 Sep 2026 · Company Update / Acquisition
Newspaper Advertisement regarding Completion of Dispatch of Annual Report for FY 2025-26 and Notice of 5th Annual General Meeting to the Members of the Company4 Sep 2026 · Company Update / Newspaper Publication
Credit Rating issued by India Ratings & Research Private Limited3 Sep 2026 · Company Update / Credit Rating
Letter to Shareholders under Regulation 36(1)(b) of SEBI (LODR) Regulations, 20153 Sep 2026 · Company Update / General
Notice of 5th AGM and Annual Report for FY 2025-263 Sep 2026 · AGM/EGM / AGM
Annual Report for FY 2025-26.3 Sep 2026 · Others / Reg. 34 (1) Annual Report
Newspaper Advertisement w.r.t. 5th AGM of the Company.31 Aug 2026 · Company Update / Newspaper Publication
Copy of Newspaper Publication of Financial Results for the quarter ended June 30, 2026.12 Aug 2026 · Company Update / Newspaper Publication
Monitoring Agency Report for the quarter ended June 30, 202610 Aug 2026 · Company Update / Monitoring Agency Report
Opening of a new Corporate Office of the Company10 Aug 2026 · Company Update / General
Change in the Registered Office address of the Company, subject to the approval of shareholders and other Statutory Authorities.10 Aug 2026 · Company Update / Change in Registered Office Address
Investment in Wholly Owned Subsidiary.10 Aug 2026 · Company Update / Acquisition
Re-appointment of Managing Director, Independent Director and Continuation of Directorship of Non- Executive Director.10 Aug 2026 · Company Update / Change in Directorate
Audited Standalone and Consolidated Financial Results for quarter ended June 30, 2026.10 Aug 2026 · Result / Financial Results
Audited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026.10 Aug 2026 · Board Meeting / Outcome of Board Meeting
Valiant Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2026 ,inter alia, to consider and approve financial results for ....5 Aug 2026 · Board Meeting / Board Meeting
for quarter ended June 30, 2026.13 Jul 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Closure of Trading Window for declaration of Financial Results for the quarter ended June 30, 2026.26 Jun 2026 · Insider Trading / SAST / Closure of Trading Window
Please find enclosed30 May 2026 · Company Update / General
Annual Secretarial Compliance Report for the Financial Year 2025-2026.22 May 2026 · Company Update / Reg.24(A)-Annual Secretarial Compliance
The Exchange has received the disclosure under Regulation 10(5) in respect of acquisition under Regulation 10(1)(a) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, ....20 May 2026 · Insider Trading / SAST / Disclosures under Reg. 10(5) in respect of acquisition under Reg. 10(1)(a) of SEBI (SAST) Reg. 2011
Please find enclosed19 May 2026 · Company Update / General
Valiant Laboratories Limited announces evaluation of Restructuring options.16 May 2026 · Company Update / Press Release / Media Release
Copy of Newspaper Publication of Financial Results for the quarter and year ended 31 March, 2026.16 May 2026 · Company Update / Newspaper Publication
Monitoring Agency Report for quarter ended March 31, 202614 May 2026 · Company Update / Monitoring Agency Report
Audited Standalone and Consolidated Financial Results for quarter and year ended March 31, 2026.14 May 2026 · Result / Financial Results
Appointment of Cost Auditor and Internal Auditor.14 May 2026 · Company Update / General
Audited Standalone and Consolidated Financial Results for quarter and year ended March 31, 2026.14 May 2026 · Result / Financial Results
Audited Standalone and Consolidated Financial Results for the quarter and year ended March 31, 2026.14 May 2026 · Board Meeting / Outcome of Board Meeting
Valiant Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/05/2026 ,inter alia, to consider and approve financial results for ....11 May 2026 · Board Meeting / Board Meeting

Corporate actions

Purpose	Ex date	Record date	Payment date
Right Issue of Equity Shares	18 Jul 2025	19 Jul 2025	—

Board meetings

2 Nov 2026 Board Meeting - Financial Results
10 Aug 2026 Board Meeting - Financial Results